These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
215 related articles for article (PubMed ID: 20801653)
1. Novel macrocyclic HCV NS3 protease inhibitors derived from α-amino cyclic boronates. Li X; Zhang YK; Liu Y; Ding CZ; Zhou Y; Li Q; Plattner JJ; Baker SJ; Zhang S; Kazmierski WM; Wright LL; Smith GK; Grimes RM; Crosby RM; Creech KL; Carballo LH; Slater MJ; Jarvest RL; Thommes P; Hubbard JA; Convery MA; Nassau PM; McDowell W; Skarzynski TJ; Qian X; Fan D; Liao L; Ni ZJ; Pennicott LE; Zou W; Wright J Bioorg Med Chem Lett; 2010 Oct; 20(19):5695-700. PubMed ID: 20801653 [TBL] [Abstract][Full Text] [Related]
2. Synthesis of new acylsulfamoyl benzoxaboroles as potent inhibitors of HCV NS3 protease. Li X; Zhang YK; Liu Y; Zhang S; Ding CZ; Zhou Y; Plattner JJ; Baker SJ; Liu L; Bu W; Kazmierski WM; Wright LL; Smith GK; Jarvest RL; Duan M; Ji JJ; Cooper JP; Tallant MD; Crosby RM; Creech K; Ni ZJ; Zou W; Wright J Bioorg Med Chem Lett; 2010 Dec; 20(24):7493-7. PubMed ID: 21041080 [TBL] [Abstract][Full Text] [Related]
3. Synthesis and biological evaluations of P4-benzoxaborole-substituted macrocyclic inhibitors of HCV NS3 protease. Ding CZ; Zhang YK; Li X; Liu Y; Zhang S; Zhou Y; Plattner JJ; Baker SJ; Liu L; Duan M; Jarvest RL; Ji J; Kazmierski WM; Tallant MD; Wright LL; Smith GK; Crosby RM; Wang AA; Ni ZJ; Zou W; Wright J Bioorg Med Chem Lett; 2010 Dec; 20(24):7317-22. PubMed ID: 21067923 [TBL] [Abstract][Full Text] [Related]
4. Novel potent macrocyclic inhibitors of the hepatitis C virus NS3 protease: use of cyclopentane and cyclopentene P2-motifs. Bäck M; Johansson PO; Wångsell F; Thorstensson F; Kvarnström I; Ayesa S; Wähling H; Pelcman M; Jansson K; Lindström S; Wallberg H; Classon B; Rydergård C; Vrang L; Hamelink E; Hallberg A; Rosenquist S; Samuelsson B Bioorg Med Chem; 2007 Nov; 15(22):7184-202. PubMed ID: 17845856 [TBL] [Abstract][Full Text] [Related]
5. Synthesis and evaluation of novel alpha-amino cyclic boronates as inhibitors of HCV NS3 protease. Li X; Zhang YK; Liu Y; Ding CZ; Li Q; Zhou Y; Plattner JJ; Baker SJ; Qian X; Fan D; Liao L; Ni ZJ; White GV; Mordaunt JE; Lazarides LX; Slater MJ; Jarvest RL; Thommes P; Ellis M; Edge CM; Hubbard JA; Somers D; Rowland P; Nassau P; McDowell B; Skarzynski TJ; Kazmierski WM; Grimes RM; Wright LL; Smith GK; Zou W; Wright J; Pennicott LE Bioorg Med Chem Lett; 2010 Jun; 20(12):3550-6. PubMed ID: 20493689 [TBL] [Abstract][Full Text] [Related]
6. Design and synthesis of depeptidized macrocyclic inhibitors of hepatitis C NS3-4A protease using structure-based drug design. Venkatraman S; Njoroge FG; Girijavallabhan VM; Madison VS; Yao NH; Prongay AJ; Butkiewicz N; Pichardo J J Med Chem; 2005 Aug; 48(16):5088-91. PubMed ID: 16078825 [TBL] [Abstract][Full Text] [Related]
7. Inhibitors of hepatitis C virus NS3/4A: alpha-ketoamide based macrocyclic inhibitors. Avolio S; Robertson K; Hernando JI; DiMuzio J; Summa V Bioorg Med Chem Lett; 2009 Apr; 19(8):2295-8. PubMed ID: 19285390 [TBL] [Abstract][Full Text] [Related]
8. Development of macrocyclic inhibitors of HCV NS3/4A protease with cyclic constrained P2-P4 linkers. Rudd MT; McIntyre CJ; Romano JJ; Butcher JW; Holloway MK; Bush K; Nguyen KT; Gilbert KF; Lyle TA; Liverton NJ; Wan BL; Summa V; Harper S; Rowley M; Vacca JP; Carroll SS; Burlein C; DiMuzio JM; Gates A; Graham DJ; Huang Q; Ludmerer SW; McClain S; McHale C; Stahlhut M; Fandozzi C; Taylor A; Trainor N; Olsen DB; McCauley JA Bioorg Med Chem Lett; 2012 Dec; 22(23):7207-13. PubMed ID: 23084906 [TBL] [Abstract][Full Text] [Related]
9. Novel macrocyclic inhibitors of hepatitis C NS3/4A protease featuring a 2-amino-1,3-thiazole as a P4 carbamate replacement. Di Francesco ME; Dessole G; Nizi E; Pace P; Koch U; Fiore F; Pesci S; Di Muzio J; Monteagudo E; Rowley M; Summa V J Med Chem; 2009 Nov; 52(22):7014-28. PubMed ID: 19856919 [TBL] [Abstract][Full Text] [Related]
10. Bismacrocyclic inhibitors of hepatitis C NS3/4a protease. McCauley JA; Rudd MT; Nguyen KT; McIntyre CJ; Romano JJ; Bush KJ; Varga SL; Ross CW; Carroll SS; DiMuzio J; Stahlhut MW; Olsen DB; Lyle TA; Vacca JP; Liverton NJ Angew Chem Int Ed Engl; 2008; 47(47):9104-7. PubMed ID: 18925594 [No Abstract] [Full Text] [Related]
11. Novel potent hepatitis C virus NS3 serine protease inhibitors derived from proline-based macrocycles. Chen KX; Njoroge FG; Arasappan A; Venkatraman S; Vibulbhan B; Yang W; Parekh TN; Pichardo J; Prongay A; Cheng KC; Butkiewicz N; Yao N; Madison V; Girijavallabhan V J Med Chem; 2006 Feb; 49(3):995-1005. PubMed ID: 16451065 [TBL] [Abstract][Full Text] [Related]
12. Synthesis and antiviral activity of HCV NS3/4A peptidomimetic boronic acid inhibitors. Boloor A; Hanway D; Joshi M; Winn DT; Mendez G; Walls M; Wei P; Qian F; Zhang X; Zhang Y; Hepperle ME; Li X; Campbell DA; Betancort JM Bioorg Med Chem Lett; 2009 Oct; 19(19):5708-11. PubMed ID: 19713109 [TBL] [Abstract][Full Text] [Related]
13. Synthesis of BILN 2061, an HCV NS3 protease inhibitor with proven antiviral effect in humans. Faucher AM; Bailey MD; Beaulieu PL; Brochu C; Duceppe JS; Ferland JM; Ghiro E; Gorys V; Halmos T; Kawai SH; Poirier M; Simoneau B; Tsantrizos YS; Llinàs-Brunet M Org Lett; 2004 Aug; 6(17):2901-4. PubMed ID: 15330643 [TBL] [Abstract][Full Text] [Related]
15. Potent 7-hydroxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid-based macrocyclic inhibitors of hepatitis C virus NS3 protease. Chen KX; Njoroge FG; Pichardo J; Prongay A; Butkiewicz N; Yao N; Madison V; Girijavallabhan V J Med Chem; 2006 Jan; 49(2):567-74. PubMed ID: 16420042 [TBL] [Abstract][Full Text] [Related]
16. Synthesis, antiviral activity, and conformational studies of a P3 aza-peptide analog of a potent macrocyclic tripeptide HCV protease inhibitor. Randolph JT; Zhang X; Huang PP; Klein LL; Kurtz KA; Konstantinidis AK; He W; Kati WM; Kempf DJ Bioorg Med Chem Lett; 2008 Apr; 18(8):2745-50. PubMed ID: 18375121 [TBL] [Abstract][Full Text] [Related]
17. Development of potent macrocyclic inhibitors of genotype 3a HCV NS3/4A protease. Rudd MT; McCauley JA; Romano JJ; Butcher JW; Bush K; McIntyre CJ; Nguyen KT; Gilbert KF; Lyle TA; Holloway MK; Wan BL; Vacca JP; Summa V; Harper S; Rowley M; Carroll SS; Burlein C; DiMuzio JM; Gates A; Graham DJ; Huang Q; Ludmerer SW; McClain S; McHale C; Stahlhut M; Fandozzi C; Taylor A; Trainor N; Olsen DB; Liverton NJ Bioorg Med Chem Lett; 2012 Dec; 22(23):7201-6. PubMed ID: 23021993 [TBL] [Abstract][Full Text] [Related]
18. Molecular modeling based approach to potent P2-P4 macrocyclic inhibitors of hepatitis C NS3/4A protease. Liverton NJ; Holloway MK; McCauley JA; Rudd MT; Butcher JW; Carroll SS; DiMuzio J; Fandozzi C; Gilbert KF; Mao SS; McIntyre CJ; Nguyen KT; Romano JJ; Stahlhut M; Wan BL; Olsen DB; Vacca JP J Am Chem Soc; 2008 Apr; 130(14):4607-9. PubMed ID: 18338894 [TBL] [Abstract][Full Text] [Related]